Moderna (MRNA) Expected to Announce Quarterly Earnings on Thursday

Moderna (NASDAQ:MRNA - Get Free Report) is expected to be issuing its quarterly earnings data before the market opens on Thursday, February 27th. Analysts expect the company to announce earnings of ($2.93) per share and revenue of $977.11 million for the quarter. Parties that are interested in registering for the company's conference call can do so using this link.

Moderna Stock Performance

Shares of NASDAQ MRNA traded up $0.97 during midday trading on Friday, hitting $34.70. 11,348,029 shares of the stock traded hands, compared to its average volume of 12,856,023. The company has a market cap of $13.35 billion, a PE ratio of -3.77 and a beta of 1.59. Moderna has a one year low of $29.25 and a one year high of $170.47. The business has a 50 day moving average price of $38.17 and a two-hundred day moving average price of $53.20.

Analysts Set New Price Targets

Several brokerages recently issued reports on MRNA. Bank of America decreased their price target on Moderna from $41.00 to $34.00 and set an "underperform" rating for the company in a report on Tuesday, February 11th. Leerink Partners decreased their price target on Moderna from $31.00 to $27.00 and set an "underweight" rating for the company in a report on Thursday, January 16th. Wolfe Research began coverage on Moderna in a report on Friday, November 15th. They set an "underperform" rating and a $40.00 price target for the company. Morgan Stanley decreased their price target on Moderna from $70.00 to $38.00 and set an "equal weight" rating for the company in a report on Wednesday, January 15th. Finally, Piper Sandler reiterated an "overweight" rating and set a $69.00 price target (down previously from $115.00) on shares of Moderna in a report on Monday, November 18th. Four analysts have rated the stock with a sell rating, fifteen have issued a hold rating, three have given a buy rating and one has issued a strong buy rating to the company's stock. According to MarketBeat.com, the company presently has an average rating of "Hold" and an average price target of $60.63.

Insider Activity

In related news, insider Shannon Thyme Klinger sold 1,418 shares of the stock in a transaction dated Friday, November 29th. The stock was sold at an average price of $42.79, for a total transaction of $60,676.22. Following the sale, the insider now owns 19,717 shares of the company's stock, valued at approximately $843,690.43. This represents a 6.71 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Insiders have sold 2,664 shares of company stock valued at $115,210 in the last 90 days. Insiders own 15.70% of the company's stock.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.